Multiple Myeloma | S Vincent Rajkumar, MD

published 10 months ago by Dr Neil Love

Multiple Myeloma Update — Part 1: Our interview with Dr Rajkumar highlights the following topics as well as cases from his practice: Updated risk-stratification model for smoldering multiple myeloma (MM) incorporating the revised International Myeloma Working Group diagnostic criteria; therapeutic approach for standard- versus high-risk smoldering MM (00:00) Subcutaneous versus intravenous daratumumab administration for MM (05:28) Efficacy and tolerability of the recently FDA-approved regimen of daratumumab in combination with lenalidomide and dexamethasone for patients with previously untreated MM not eligible for autologous stem cell transplantation (ASCT) (06:52) Activity, tolerability and ongoing trials of carfilzomib- and bortezomib-based triplet regimens for newly diagnosed MM (08:55) Results of the Phase III CASSIOPEIA study: Bortezomib/thalidomide/dexamethasone with or without daratumumab for patients with newly diagnosed MM eligible for ASCT (12:39) Case: A man in his early 80s with MM initially treated with lenalidomide/bortezomib/dexamethasone and maintenance lenalidomide experiences relapse 2 years later (15:02) Benefits and risks of the Bcl-2 inhibitor venetoclax in combination with bortezomib/dexamethasone for relapsed/refractory (R/R) MM with and without the t(11;14) translocation on the Phase III BELLINI trial (16:43) Proposed mechanism of venetoclax-associated mortality in MM (19:35) Understanding the clinical role and limitations of surrogate endpoints for overall survival (24:29) Perspective on the possible design flaws in the BELLINI trial (28:08) CME information and select publications  

more episodes from Research To Practice | Oncology Videos